Elevated monocytic IL-12 and TNF-α production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy

被引:35
作者
Lamprecht, P [1 ]
Kumanovics, G [1 ]
Mueller, A [1 ]
Csernok, E [1 ]
Komocsi, A [1 ]
Trabandt, A [1 ]
Gross, WL [1 ]
Schnabel, A [1 ]
机构
[1] Univ Luebeck, Dept Rheumatol, D-23538 Lubeck, Germany
关键词
Wegener's granulomatosis; cyclophosphamide; IL-12; TNF-alpha;
D O I
10.1046/j.1365-2249.2002.01801.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Wegener's granulomatosis (WG) is characterized by a predominance of the type 1 T-helper cell (Th1) response. We have studied monocytic cytokine expression in untreated patients and in patients who did not respond to prior methotrexate or trimethoprim-sulphamethoxazole therapy, i.e. patients with active disease. Intracytoplasmic IL-12 and TNF-alpha expression was significantly increased in WG compared with healthy controls. IL-8 expression was not increased. Two and 12 weeks of daily standard oral cyclophosphamide and corticosteroid (CYC + GC) treatment induced a stable remission of the disease. Elevated IL-12 and TNF-alpha expression of monocytes was normalized. The active metabolite of CYC was shown to down-regulate IL-12 mRNA in vitro. Monocytic cytokines, especially IL-12, may have a role in the early determination and skewing of the immunoregulatory response towards a Th1 profile. It appears that CYC + GC exerts its effect by normalizing the Th1-driving cytokine pattern, and CYC may maintain this mode of action. Normalization of the skewed cytokine pattern may be a prerequisite and an indicator of inducing a remission in WG.
引用
收藏
页码:181 / 186
页数:6
相关论文
共 18 条
[1]   SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND IMMUNE-MEDIATED INFLAMMATION [J].
CHROUSOS, GP .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1351-1362
[2]   Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy [J].
Comabella, M ;
Balashov, K ;
Issazadeh, S ;
Smith, D ;
Weiner, HL ;
Khoury, SJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (04) :671-678
[3]  
Csernok E, 1999, ARTHRITIS RHEUM, V42, P742, DOI 10.1002/1529-0131(199904)42:4<742::AID-ANR18>3.3.CO
[4]  
2-9
[5]  
Csernok E., 1995, Arthritis and Rheumatism, V38, pS375
[6]  
de Groot K, 2001, CLIN NEPHROL, V55, P31
[7]  
DEGUCHI Y, 1990, CLIN EXP IMMUNOL, V81, P311
[8]  
Gross Wolfgang L., 1999, Current Opinion in Rheumatology, V11, P41, DOI 10.1097/00002281-199901000-00007
[9]   NOMENCLATURE OF SYSTEMIC VASCULITIDES - PROPOSAL OF AN INTERNATIONAL CONSENSUS CONFERENCE [J].
JENNETTE, JC ;
FALK, RJ ;
ANDRASSY, K ;
BACON, PA ;
CHURG, J ;
GROSS, WL ;
HAGEN, EC ;
HOFFMAN, GS ;
HUNDER, GG ;
KALLENBERG, CGM ;
MCCLUSKEY, RT ;
SINICO, RA ;
REES, AJ ;
VANES, LA ;
WALDHERR, R ;
WIIK, A .
ARTHRITIS AND RHEUMATISM, 1994, 37 (02) :187-192
[10]   Monocyte activation in patients with Wegener's granulomatosis [J].
Kobold, ACM ;
Kallenberg, GGM ;
Tervaert, JWC .
ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (04) :237-245